Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

967 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials.
Al-Khatib SM, Hellkamp A, Bardy GH, Hammill S, Hall WJ, Mark DB, Anstrom KJ, Curtis J, Al-Khalidi H, Curtis LH, Heidenreich P, Peterson ED, Sanders G, Clapp-Channing N, Lee KL, Moss AJ. Al-Khatib SM, et al. Among authors: moss aj. JAMA. 2013 Jan 2;309(1):55-62. doi: 10.1001/jama.2012.157182. JAMA. 2013. PMID: 23280225 Free PMC article.
Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004.
Al-Khatib SM, Sanders GD, Mark DB, Lee KL, Bardy GH, Bigger JT, Buxton AE, Connolly S, Kadish A, Moss A, Feldman AM, Ellenbogen KA, Singh S, Califf RM; Expert panel participating in a Duke Clinical Research Institute-sponsored conference. Al-Khatib SM, et al. Am Heart J. 2005 Jun;149(6):1020-34. doi: 10.1016/j.ahj.2005.02.005. Am Heart J. 2005. PMID: 15976783 Review.
Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials.
Hess PL, Laird A, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Hall WJ, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Al-Khatib SM, Piccini JP, Inoue LY, Sanders GD. Hess PL, et al. Among authors: moss aj. Heart Rhythm. 2013 Jun;10(6):828-35. doi: 10.1016/j.hrthm.2013.02.011. Epub 2013 Feb 13. Heart Rhythm. 2013. PMID: 23416381 Free PMC article.
Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator?
Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton AE, Cappato R, Dorian P, Hallstrom A, Kadish AH, Kudenchuk PJ, Lee KL, Mark DB, Moss AJ, Steinman R, Inoue LY, Sanders GD. Al-Khatib SM, et al. Among authors: moss aj. Int J Cardiol. 2014 Mar 1;172(1):253-4. doi: 10.1016/j.ijcard.2013.12.278. Epub 2014 Jan 10. Int J Cardiol. 2014. PMID: 24467982 No abstract available.
Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials.
Pun PH, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Hess PL, Inoue LY, Sanders GD. Pun PH, et al. Among authors: moss aj. Am J Kidney Dis. 2014 Jul;64(1):32-9. doi: 10.1053/j.ajkd.2013.12.009. Epub 2014 Feb 8. Am J Kidney Dis. 2014. PMID: 24518128 Free PMC article.
Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials.
Steinberg BA, Al-Khatib SM, Edwards R, Han J, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LY, Sanders GD. Steinberg BA, et al. Among authors: moss aj. JACC Heart Fail. 2014 Dec;2(6):623-9. doi: 10.1016/j.jchf.2014.06.007. Epub 2014 Oct 8. JACC Heart Fail. 2014. PMID: 25306452 Free PMC article.
Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.
Hess PL, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton A, Cappato R, Dorian P, Hallstrom A, Kadish AH, Kudenchuk PJ, Lee KL, Mark DB, Moss AJ, Steinman R, Inoue LY, Sanders G. Hess PL, et al. Among authors: moss aj. Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2):179-86. doi: 10.1161/CIRCOUTCOMES.114.001306. Epub 2015 Feb 10. Circ Cardiovasc Qual Outcomes. 2015. PMID: 25669833 Free PMC article.
New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.
Friedman DJ, Al-Khatib SM, Zeitler EP, Han J, Bardy GH, Poole JE, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LYT, Sanders GD. Friedman DJ, et al. Among authors: moss aj. Am Heart J. 2017 Sep;191:21-29. doi: 10.1016/j.ahj.2017.06.002. Epub 2017 Jun 9. Am Heart J. 2017. PMID: 28888266 Free PMC article. Review.
Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes.
Sharma A, Al-Khatib SM, Ezekowitz JA, Cooper LB, Fordyce CB, Michael Felker G, Bardy GH, Poole JE, Thomas Bigger J, Buxton AE, Moss AJ, Friedman DJ, Lee KL, Steinman R, Dorian P, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Peterson ED, Inoue LYT, Sanders GD. Sharma A, et al. Among authors: moss aj. Eur J Heart Fail. 2018 Jun;20(6):1031-1038. doi: 10.1002/ejhf.1192. Epub 2018 May 15. Eur J Heart Fail. 2018. PMID: 29761861 Free article. Clinical Trial.
967 results